quinazolines has been researched along with Li-Fraumeni Syndrome in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arribas, J; Baselga, J; Caratù, G; De Mattos-Arruda, L; Felip, E; Grueso, J; Hernández-Losa, J; Nuciforo, P; Parra, JL; Prudkin, L; Puente, XS; Scaltriti, M; Seoane, J; Serra, V; Silberschmidt, D; Vivancos, A | 1 |
| Ali, SM; Chan, CA; Halmos, B; Jia, Y; Miller, VA; Saad, S | 1 |
| Calcasola, M; Cane, P; Izatt, L; Michalarea, V; Spicer, J; Tobal, K | 1 |
3 other study(ies) available for quinazolines and Li-Fraumeni Syndrome
| Article | Year |
|---|---|
Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation.
Topics: Adult; Exome; Female; Humans; Lapatinib; Li-Fraumeni Syndrome; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Tumor Cells, Cultured | 2013 |
Successful treatment of a patient with Li-Fraumeni syndrome and metastatic lung adenocarcinoma harboring synchronous EGFR L858R and ERBB2 extracellular domain S310F mutations with the pan-HER inhibitor afatinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Agents; ErbB Receptors; Female; Humans; Li-Fraumeni Syndrome; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Receptor, ErbB-2 | 2014 |
EGFR-mutated lung cancer in Li-Fraumeni syndrome.
Topics: Adult; Breast Neoplasms; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Li-Fraumeni Syndrome; Lung Neoplasms; Middle Aged; Mutation; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome; Tumor Suppressor Protein p53; Young Adult | 2014 |